Tawesak Tanwandee
Overview
Explore the profile of Tawesak Tanwandee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
2441
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shiina S, Maikhuu J, Deng Q, Batsaikhan T, Canseco L, Tobari M, et al.
Clin Mol Hepatol
. 2025 Mar;
PMID: 40037692
Liver disease has emerged as a critical and escalating public health concern worldwide, with the Asia-Pacific region at the forefront of this challenge due to its vast population and diverse...
2.
Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C, et al.
Hepatol Int
. 2025 Feb;
PMID: 40016576
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association...
3.
Choudhury A, Kulkarni A, Arora V, Soin A, Dokmeci A, Chowdhury A, et al.
Hepatol Int
. 2025 Feb;
19(1):1-69.
PMID: 39961976
Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the...
4.
Chen J, Jia J, Zhuang H, Zhang W, Yang J, Tanwandee T, et al.
Hepatol Int
. 2025 Feb;
PMID: 39900677
Background: The Asia-Pacific (AP) region carries a substantial burden of HBV. Affordable HBV treatment is crucial to attain WHO's elimination goal. This study assesses the pricing and affordability of HBV...
5.
Lau G, Obi S, Zhou J, Tateishi R, Qin S, Zhao H, et al.
Hepatol Int
. 2024 Nov;
18(6):1661-1683.
PMID: 39570557
In Asia-Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs...
6.
Khongsaengbhak T, Atthakitmongkol T, Tanwandee T
Hepat Med
. 2024 Nov;
16:81-89.
PMID: 39534784
Background: Thyrotoxicosis is often associated with abnormal liver tests. This study aimed to characterize the clinical features and laboratory findings in thyrotoxic patients with liver abnormalities and to identify predictive...
7.
Alboraie M, Tanwandee T, Xu X, Nikolova D, Estupinan E, Ghazinyan H, et al.
Ann Hepatol
. 2024 Oct;
29(6):101573.
PMID: 39477629
No abstract available.
8.
Mohamed R, Wang W, Tanwandee T, Hasan I, Pham C, Lim Y, et al.
J Gastrointest Cancer
. 2024 Jul;
55(3):1333-1344.
PMID: 38995318
Purpose: In several Asian countries, hepatocellular carcinoma (HCC) is a leading cause of cancer deaths. HCC risk factors in Asia differ from those elsewhere and are changing with the treatment...
9.
Kohler B, Bes M, Chan H, Esteban J, Piratvisuth T, Sukeepaisarnjaroen W, et al.
Int J Biol Markers
. 2024 Mar;
39(2):107-117.
PMID: 38549363
Introduction: Diagnosis of cholangiocarcinoma (CCA) can be challenging due to unclear imaging criteria and difficulty obtaining adequate tissue biopsy. Although serum cancer antigen 19-9 and carcinoembryonic antigen have been proposed...
10.
Sriphoosanaphan S, Pantumongkol W, Kulpeng W, Charonpongsuntorn C, Tanwandee T, Sukeepaisarnjaroen W, et al.
PLoS One
. 2024 Mar;
19(3):e0300327.
PMID: 38512900
Background: Clinical trials have proven the efficacy and safety of atezolizumab combined with bevacizumab (A+B) in treating unresectable hepatocellular carcinoma (uHCC). This study aimed to assess the cost-utility of A+B...